Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Orexo AB (publ)

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as an ADS on the OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

Novo Holdings

Apex Venture Partners

Auriga Partners

Sofinnova Investments

Crédit Lyonnais Private Equity

HealthCap

Orexo AB publ

🎥 DISCOVER OUR STORY. Orexo has come a long way since we started out in the mid 1990s as a research and development company in Uppsala, Sweden. 

Today we develop improved pharmaceuticals and digital therapies addressing unmet patient needs primarily within the growing space of substance use disorders and mental health. Our products are commercialized by Orexo in the United States or via partners worldwide.
 
We’re so proud of the difference we’re making to patients’ lives, and we want to do even more. 
 
#transformation #leadership #whatwedomatters

NEWS: Today Orexo is filing a New Drug Application to the FDA for OX124, our life-saving medication that reverses the effects of powerful synthetic opioids.
 
OX124 is a nasal rescue medication that contains a high dose of naloxone. It’s easy to administer, absorbed fast, and is effective against even the most powerful opioids. 
 
Every year across the US, tens of thousands of people, many of whom are young, die from opioid overdoses. Synthetic opioids, including illicitly manufactured fentanyl, cause most of these deaths. 
 
We’re dedicated to saving lives for vulnerable and often stigmatized patients, and now we’re one step closer.

#opioidcrisis #fentanyl #makeadifference 
 
Read our press release.
https://bit.ly/3JCNCUf

Yesterday we went out with our Full Year Report, also including the latest development in Q4. 

In the quarter we saw growth in net revenues (8.4%), while EBITDA decreased (9.5%). The development is mainly driven by a stronger USD & continued investment in FUTURE GROWTH DRIVERS such as the NDA filing of OX124 & the MODIA clinical study. 

Additionally, we are in a patent litigation protecting the intellectual properties for our lead medication, which is a costly process also affecting the financial result.

OX124 💠 opioid overdose rescue medication  
MODIA 💠 digital therapy for opioid dependence

#opioidcrisis #USA #buildingforthefuture 

For details & priorities going forward read the CEO Comments here:
https://lnkd.in/g4thsfE

New BLOG post out: “We lost our youngest son, Charlie, to a single counterfeit Percocet.”

When Edward Ternan discovered his son had tragically overdosed on a fake pill, he also learned that Charlie wasn’t the only victim of the #fentanyl crisis. 

Why are so many young people overdosing on illegally manufactured synthetic fentanyl pills that look like legitimate prescription medications?

Edward answers this question and explains how we can protect young people and prevent more lives being lost.

#opioidcrisis #OX124 #OX125 #lifematters 

https://bit.ly/3XIindZ

As we enter 2023, many of us are likely to be reflecting on the goals we’ve set ourselves for the year ahead. 
 
New Year goals are often about changing our behaviours to improve our health, like giving up smoking or eating healhier food.
 
Patients living with an addiction, such as to opioids, often see the start of the year as an opportunity to seek treatment. 
 
At Orexo, we know that combining traditional pharmacological treatments with evidence-based digital therapeutics is highly effective for people trying to overcome addictions. 
 
We’re proud that our digital therapeutics are making a difference to these patients and this year we want to help even more patients reach their goal of overcoming their addiction. 

Learn more ▶https://lnkd.in/dnsphjz3

#opioids #alcohol #depression #digitalhealthcare

NEWS: Today we are glad to announce we are commencing 2 feasibility studies testing our versatile drug delivery platform amorphOX® also with biomolecules and vaccine. The trials are conducted along with leading biotech companies.

Read PR here ▶ https://bit.ly/3ZmCe47

#innovation #drugdiscovery

Season’s greetings to our community followers and not at least our employees and other stakeholders who are key for our success. 

At Orexo we stand in solidarity beside the people of the Ukraine during this tragic time. We remain deeply concerned for all those affected by this war. As we now are approaching a time when many people around the world are gathering with their closest ones to celebrate season holiday the Ukrainian people are in need of protection and shelter. 

Ahead of the season holiday we have extended our support to the UNHCR to help those in need. 

#westandwithukraine

Read more about the UNHCR’s fundraising here: https://bit.ly/3HBJ9fC

NEWS: M.D. Edward Kim, from psychiatrist to Chief Medical Officer. In this in-depth interview Ed share his reasons for joining Orexo and how he’s supporting the company in its core mission to combat the US opioid crisis. 

#advocacy #accesstocare #digitalhealth 

Read the more here ▶

https://bit.ly/3v8GdU3

We talked to Megan Coder, founder of the Digital Therapeutics Alliance about the power of DTx - the new clinically proven treatment solutions. Read the interview to find out more about digital therapeutics and how they can be used to improve patients’ health outcomes. Link here ▶ https://bit.ly/3PkBAzG 

#digitalhealth #accesstocare #mentalhealth

Packing for a trip and realising your auto-injector is about to expire is just one of those things for the many people living with severe allergies. 
 
If you’re someone who can’t go anywhere without your auto-injector, it can be more than just an inconvenience. 
 
Epinephrine (adrenaline) is the first-line treatment for anaphylaxis but it’s very unstable. It can’t cope with hanging around in an auto-injector for months on end and it doesn’t enjoy the things you do like hot beaches or snowy slopes. 
 
That’s why at Orexo, we’ve developed something different. 
 
OX640 is a groundbreaking nasal adrenaline. 
 
No more auto-injectors. Longer lasting. Stable at a wider range of temperatures. 
 
Freedom to go where you want to. 
 
Stable in any life situation.

ORX

COM:OREXO

Orexo

Last Close

10.92

31/10 16:29

Market Cap

685.55M

Beta: -

Volume Today

15.97K

Avg: -